
Spectrum Pharmaceuticals Investor Relations Material
Latest events

Q4 2022
Spectrum Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Spectrum Pharmaceuticals Inc
Access all reports
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing and commercializing oncology and hematology drug products. It operates through the following segments: North American Sales, International Sales, and Research and Development. The company's product candidates include FUSILEV , ZEVALIN, VALSTAR, GAMMATOPHOS, KYTRIL, SUTENT, and VORAXAZE. It offers FUSILEV (levoleucovorin) oral granules, ZEVALIN (ibritumomab tiuxetan) for injection for the treatment of patients with indolent non-Hodgkin's lymphoma monitored by x-ray prior to treatment and during treatment cycle number one; cancer of the ovary or fallopian tube. Spectrum Pharmaceuticals, Inc. is based in Henderson, Nevada.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
SPPI
Country
🇺🇸 United States